

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10509078
Filing Date		2004-09-27
First Named Inventor	Ahmed et al.	
Art Unit		
Examiner Name	Not Assigned	
Attorney Docket Number	P33024	

U.S. PATENTS

[Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5596001	A	1997-01-21	Ernest S. Hamanaka	
	2	6172084	B1	2001-01-09	Cuny et al.	
	3	6207679	B1	2001-03-27	Cuny et al.	
	4	6310212	B1	2001-10-30	Yuan et al.	
	5	6376670	B1	2002-04-23	Cuny et al.	
	6	6380199	B1	2002-04-30	Reavill et al.	
	7	6787535	B2	2004-09-07	Beard et al.	
	8	5576338	A	1996-11-19	Friesen et al. (equiv. of CA2169231)	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10509078
Filing Date	2004-09-27
First Named Inventor	Ahmed et al.
Art Unit	
Examiner Name	Not Assigned
Attorney Docket Number	P33024

	9	6187805	B1	2001-02-13	Pineiro et al. (equivalent of GB2341549)	
--	---	---------	----	------------	--	--

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040024210	A1	2004-02-05	Johansson et al.	
	2	20040167030	A1	2004-08-26	Berontas et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS

Remove

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2169231	CA		1996-08-16	Friesen et al. (see US equivalent 5576338)		<input type="checkbox"/>
	2	0605981	EP	B1	1996-02-21	Kirk/Minnesota Mining & Manufacturing Co.		<input type="checkbox"/>
	3	0631176	EP	B1	2000-12-13	Kirk et al.		<input type="checkbox"/>
	4	0867477	EP	B1	2002-05-02	Moretti et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10509078
Filing Date		2004-09-27
First Named Inventor	Ahmed et al.	
Art Unit		
Examiner Name	Not Assigned	
Attorney Docket Number		P33024

5	818449	EP	A1	1998-01-14	Adir & Cie		<input type="checkbox"/>
6	2341549	GB		2000-03-22	Pineiro et al. (see US equivalent 6187805)		<input type="checkbox"/>
7	02262627	JP		1990-10-25	Sugiyama et al. (English Abstract)		<input checked="" type="checkbox"/>
8	0013681	WO	A2	2000-03-16	Gillespie et al.		<input type="checkbox"/>
9	0034265	WO	A2	2000-06-15	Cuny/Sepracor Inc.		<input type="checkbox"/>
10	0042026	WO	A1	2000-07-20	Teng et al.		<input type="checkbox"/>
11	0058303	WO	A1	2000-10-05	Yuan et al.		<input type="checkbox"/>
12	0058313	WO	A1	2000-10-05	Yuan/Neurogen Corp.		<input type="checkbox"/>
13	0063203	WO	A1	2000-10-26	Slassi et al.		<input type="checkbox"/>
14	0064877	WO	A1	2000-11-02	Yuan et al.		<input type="checkbox"/>
15	0116108	WO	A2	2001-03-08	Zhi/Ligand Pharmaceuticals Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10509078
Filing Date		2004-09-27
First Named Inventor	Ahmed et al.	
Art Unit		
Examiner Name	Not Assigned	
Attorney Docket Number		P33024

	16	0132646	WO	A2	2001-05-10	SmithKline Beecham plc		<input type="checkbox"/>
	17	0132660	WO	A1	2001-05-10	Xin/NPS Allelix Corp.		<input type="checkbox"/>
	18	0140217	WO	A1	2001-06-07	Barth et al.		<input type="checkbox"/>
	19	0208178	WO	A1	2002-01-31	Jossan/Biovitrum Ab		<input type="checkbox"/>
	20	02098857	WO	A1	2002-12-12	Beard et al.		<input type="checkbox"/>
	21	02102774	WO	A1	2002-12-27	Briggs et al.		<input type="checkbox"/>
	22	0220489	WO	A2	2002-03-14	Bi et al.		<input type="checkbox"/>
	23	0236562	WO	A2	2002-05-10	Kelly/American Home Products Corp.		<input type="checkbox"/>
	24	0244170	WO	A2	2002-06-06	Del Castillo Nieto et al.		<input type="checkbox"/>
	25	03011284	WO	A1	2003-02-13	Pharmacia		<input type="checkbox"/>
	26	03013510	WO	A1	2003-02-20	Bromidge et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10509078
Filing Date		2004-09-27
First Named Inventor	Ahmed et al.	
Art Unit		
Examiner Name	Not Assigned	
Attorney Docket Number		P33024

27	03037872	WO	A1	2003-05-08	Chapdelaine/ Astrazeneca AB		<input type="checkbox"/>
28	03072558	WO	A2	2003-09-04	Tenbrink et al.		<input type="checkbox"/>
29	03080608	WO	A2	2003-10-02	Johnson/Glaxo Group Limited		<input type="checkbox"/>
30	04000828	WO	A1	2003-12-31	Johansson/Biovitrum AB		<input type="checkbox"/>
31	200228837	WO	A1	2002-04-11	Janssen		<input type="checkbox"/>
32	200236562	WO	A2	2002-05-10	AHP		<input type="checkbox"/>
33	9511592	WO	A1	1995-05-04	Anthoni et al.		<input type="checkbox"/>
34	9732858	WO	A1	1997-09-12	Nakai et al.		<input type="checkbox"/>
35	9827081	WO	A1	1998-06-25	Bromidge et al.		<input type="checkbox"/>
36	9847874	WO	A1	1998-10-29	Huang/Janssen Pharmaceutica NV		<input type="checkbox"/>
37	9854157	WO	A1	1998-12-03	Spada/Rhone-Poulenc Rorer Pharmaceuticals Inc.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10509078
Filing Date		2004-09-27
First Named Inventor	Ahmed et al.	
Art Unit		
Examiner Name	Not Assigned	
Attorney Docket Number		P33024

	38	9854158	WO	A1	1998-12-03	Myers/Rhone-Poulenc Rorer Pharmaceuticals Inc.		<input type="checkbox"/>
	39	9857931	WO	A2	1998-12-23	Sepracor		<input type="checkbox"/>
	40	9857952	WO	A1	1998-12-23	Kumaravel/Sepracor Inc.		<input type="checkbox"/>
	41	9947516	WO	A1	1999-09-23	Slassi et al.		<input type="checkbox"/>
	42	9965906	WO	A1	1999-12-23	Maddaford et al.		<input type="checkbox"/>
	43	0012073	WO	A1	2000-03-09	Reavill et al.		<input type="checkbox"/>
	44	03066056	WO	A1	2003-08-14	Foley et al.		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Ahmed et al. Bioorganic & Medicinal Chemistry Letters, 15: 4867-4871 (2005).	<input type="checkbox"/>
	2	Bourson et al. British Journal of Pharmacology, 125: 1562-1566 (1998).	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10509078
	Filing Date		2004-09-27
	First Named Inventor	Ahmed et al.	
	Art Unit		
	Examiner Name	Not Assigned	
	Attorney Docket Number		P33024

3	Sleight et al. British Journal of Pharmacology, 124: 556-562 (1998).	<input type="checkbox"/>
4	Bentley et al. British Journal of Pharmacology, 126: 1537-1542 (1999).	<input type="checkbox"/>
5	Bentley et al. British Journal of Pharmacology (Supplement), 126: 66 (1999).	<input type="checkbox"/>
6	Thome et al. Journal of Neural Transmission, 108: 1175-1180 (2001).	<input type="checkbox"/>
7	Bentley et al. Journal of Psychopharmacology (Supplement), A64: 255 (1997).	<input type="checkbox"/>
8	Foley et al. Neuropsychopharmacology, 29: 93-100 (2004).	<input type="checkbox"/>
9	Tsai et al. Neuroscience Letters, 276: 138-139 (1999).	<input type="checkbox"/>
10	Kan et al. Neuroscience Letters, 372: 27-29 (2004).	<input type="checkbox"/>
11	Bourson et al. The Journal of Pharmacology & Experimental Therapeutics, 274: 173-180 (1995).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10509078
Filing Date	2004-09-27
First Named Inventor	Ahmed et al.
Art Unit	
Examiner Name	Not Assigned
Attorney Docket Number	P33024

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10509078
Filing Date	2004-09-27
First Named Inventor	Ahmed et al.
Art Unit	
Examiner Name	Not Assigned
Attorney Docket Number	P33024

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☒ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/AlysonWKeating/	Date (YYYY-MM-DD)	2006-10-10
Name/Print	Alyson W. Keating	Registration Number	58045

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.